Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib Adapted to Response in Patients Diagnosed With Chronic Lymphatic Leukemia

NCT05360758 is registered in ClinicalTrials.gov with Grupo Argentino de Tratamiento de la Leucemia Aguda as lead sponsor.

NCT NCT05360758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05360758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib Adapted to Response in Patients Diagnosed With Chronic Lymphatic Leukemia
Lead sponsor
Grupo Argentino de Tratamiento de la Leucemia Aguda
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2023
Completion date
December 1, 2025
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia